Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.46 |
| ▸ | RXRB | P28702 | 9/20 | 0.46 |
| ▸ | RXRG | P48443 | 9/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935667 | 0.87 | NR1H2 (0.53) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL4936165 | 0.86 | NR1H2 (0.42) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL4943169 | 0.86 | NR1H2 (0.51) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL1679399 | 0.85 | NR1H2 (0.37) | NR1H2NR1H3ERN1S1PR1KIF11 | |
| SCHEMBL1678373 | 0.82 | RXRA (0.39) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL1678895 | 0.77 | NR1H2 (0.47) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL1679381 | 0.77 | NR1H2 (0.34) | RXRANR1H2NR1H3PPARDKIF11 | |
| SCHEMBL4940004 | 0.74 | RXRA (0.48) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL1679125 | 0.73 | NR1H2 (0.38) | RXRARXRBRXRGNR1H2NR1H3 | |
| SCHEMBL1679135 | 0.73 | NR1H2 (0.76) | RXRARXRBRXRGNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | RXRA 5/4885RXRB 4/4885RXRG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.